Stock FAQs

The Computershare CIP ("CIP") allows investors of Pfizer Inc. to directly purchase and sell shares of company common stock and reinvest dividends. You can learn more about the CIP by contacting Computershare. Please see details below.

Computershare CIP c/o Computershare Investor Services
P.O. BOX 43006
Providence RI 02940-3006

Be sure to include your name, address, daytime phone number, account number, company name (as shown on your statement) on all correspondence.

+1-800-PFE-9393 (+1-800-733-9393) (U.S. and Canada)
+1-781-575-4591. (Outside U.S. and Canada)

www-us.computershare.com/investor

The CIP is a direct stock purchase and dividend reinvestment plan administered by Computershare Trust Company, N.A., not by Pfizer. Please contact Computershare for further information.

Dividends are paid by check, or they may be directly deposited into a bank account of your choice. Most major domestic banks and financial institutions allow for direct deposit. To enroll in the Direct Deposit of Dividends Service, complete and sign an Authorization Form and send it with a voided check to Computershare. For informaton on dividend and stock split history, click here.

The principal market for our Common Stock is the New York Stock Exchange and our stock is also traded on various United States regional stock exchanges.

PFE

Dividends are usually paid in the months of March, June, September and December.

If your stock certificate is lost, stolen, or destroyed, notify Computershare immediately at (800) 733-9393. They will place a "stop transfer" on the certificate and give you instructions on how to replace your stock certificate. You will be asked to complete an Affidavit of Lost Stock Certificate. A surety bond and a premium of approximately 3% of the market value of the shares will also be required.

If you believe your dividend check has been lost or stolen, call Computershare immediately at (800) 733-9393. Computershare will place a "stop payment" order against the original check and issue you a replacement check.

Pfizer has a tool to determine the cost-basis for your Pfizer stock. To learn more please visit our cost-basis calculator tool.

Book-entry form of registered ownership allows you to own shares without having paper stock certificates in your possession. You are the record owner and enjoy the same shareholder benefits as you would with certificated shares.

Book-entry ownership eliminates some of the problems associated with paper certificates such as storage and safety of securities. Book-entry shares also eliminate the requirement for physical movement of stock certificates at the time of sale or transfer of ownership.

If you hold your book-entry shares through the Shareholder Investment Program you will receive a statement at the end of every month in which an investment or other stock activity takes place. If you have book-entry shares but do not participate in the Shareholder Investment Program, you will receive a statement of your holdings on a yearly basis. You may, of course, request an additional statement at any time by contacting Computershare.

Yes. Simply send your certificates to Computershare with written instructions to deposit them in your account as book-entry items. Do not endorse the certificates or complete the assignment section. We recommend that you send your certificates by certified or registered mail and insure them for 3% of the market value of the stock.

You may request stock certificates for the whole shares in your book-entry account at any time. Simply contact Computershare with your request and a stock certificate for the requested number of whole shares will be sent to you within 7-10 business days.

As a Pfizer shareholder of record, you have the option of depositing your dividends electronically into your bank or other financial institution on each dividend payment date through the Direct Deposit of Dividends Service.

With direct deposit, your dividend funds are available to you on the dividend payment date. This means no waiting for checks to come in the mail, no trips to the bank to make deposits, and no waiting for the checks to clear.

Instead of a check, you will receive a dividend payment statement from Pfizer. This statement will advise you of the amount of the dividend deposited, where it was deposited and the date of deposit. Of course, your bank statement will also reflect the electronic deposit.

The Direct Deposit of Dividends Service is available to you if your shares of Pfizer common stock are held in your own name. If your shares are held through a broker, you must first have the shares transferred into your own name in order to be eligible for the Pfizer Direct Deposit of Dividends Service.

You must complete and sign the Authorization Form and send it to:
Pfizer Inc.
c/o Computershare
Providence RI 02940-3006

If you change banks or accounts, you must notify Computershare of the change and include your new bank account number. If you decide not to participate in direct deposit any longer, you must notify Computershare of that decision. We will gladly make any change as soon as we are notified.

Computershare
P.O. BOX 43006
Providence RI 02940-3006
(800) PFE-9393
www.computershare.com

If you have had a legal name change, you must re-register your shares. If your shares are held in a record account at Computershare, complete a Transfer of Ownership Form and send the form and your stock certificates to Computershare. If your shares are held in a book-entry or Shareholder Investment Program account, you still must complete and submit a Transfer of Ownership Form.

We suggest that you send your certificates by certified or registered mail and insure them for 3% of the current market value.

All requests for address changes may be made by telephone, e-mail or letter. Contact Computershare and be sure to include the exact name as shown on the registration of your shares, your social security number, account number and previous address. This will help us identify your account accurately.

If your registered shares are held in certificate form: Complete a Transfer Request Form, which can be found here , and send the form and your stock certificates to Computershare, Pfizer's transfer agent. If your shares are held in book-entry form, you still must complete and submit a Transfer Request Form, which can be found here. If your shares are held by a bank or broker, please contact that firm for instructions.

Pfizer Inc. Stock Split History

You can access our interactive Annual Report by clicking here.

These are the links to our most recent proxy statement, 10-K Report and 10-Q Report. If you require a printed copy of any of these documents click here to make a request via email.

If you have two or more accounts in the same name, contact Computershare and ask to have your accounts consolidated. With respect to two or more shareholders who share the same address, we mail a single Annual Report and proxy statement to the household unless a shareholder notifies Computershare that he/she would like individual copies.

Effective October 3, 2022 Pfizer Inc. completed its acquisition of Biohaven Pharmaceutical Holding Company Ltd. Pursuant to the terms of the merger, former Biohaven shareholders will receive $148.50, in cash (without interest and less any applicable withholding taxes) for each Biohaven common share they owned as of the effective time of the merger. Additionally, pursuant to the terms of the separation and distribution agreement, former Biohaven shareholders will receive one common share of Biohaven Ltd., a new company that retained Biohaven’s non-CGRP development stage pipeline compounds, holds the Kv7 ion channel activators, glutamate modulation, and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure assets excluded from the Pfizer acquisition, for every two shares of Biohaven common shares they owned as of the record date, September 26, 2022.

Pfizer has appointed Computershare Trust Company, N.A. as paying agent for payment of the merger consideration. Additional information will be mailed to Biohaven registered shareholders outlining the steps to be taken to obtain the merger consideration. Shareholders do not need to take any action regarding their shares until contacted by the paying agent. For additional information, please contact Computershare Trust Company at 1-800-546-5141 (from within the USA, US territories and Canada), 1-781-575-2765 (from outside the USA, US territories and Canada). If you own your shares through a bank, brokerage firm or other nominee (in “street name”), please contact your bank, broker or nominee for further information about receiving the merger consideration.

Biohaven Ltd. has appointed American Stock Transfer & Trust Company, LLC as transfer agent for distribution of the common shares of Biohaven Ltd. Shareholders do not need to take any action to receive common shares of Biohaven Ltd. For Biohaven shareholders who owned Biohaven common shares in registered form as of the record date, the transfer agent will credit such shareholders with the applicable amount of Biohaven Ltd. common shares to book entry accounts established in their names to hold such shares, and will thereafter send shareholders a statement reflecting their ownership of Biohaven Ltd. common shares. For Biohaven shareholders who own Biohaven common shares through a bank, broker or other nominee (in “street name”), such bank, broker or other nominee will credit such shareholders’ accounts with their applicable common shares of Biohaven Ltd. No fractional common shares of Biohaven Ltd. will be issued to Biohaven shareholders as part of the distribution or credited to book entry accounts. In lieu of receiving fractional shares, each holder of Biohaven common shares who would otherwise be entitled to receive a fractional common share of Biohaven Ltd. will receive cash for such fractional interest, which generally will be taxable to such holder. For additional information, please contact American Stock & Trust Company at +1-800-937-5449.

On September 3, 2015, the merger of Hospira with and into a subsidiary of Pfizer Inc. (“Pfizer”) was completed. As a result of the merger, the Hospira common stock ceased trading on the New York Stock Exchange and former Hospira shareholders became entitled to receive the per share merger consideration (“merger consideration”) of $90.00, in cash (without interest and less any applicable withholding and transfer taxes) for each share of Hospira common stock they owned as of September 3, 2015, unless they have properly exercised and perfected and not withdrawn their demand for appraisal rights under Delaware law with respect to such shares. For example, if you own 100 shares of Hospira common stock, you will receive $9,000 in cash, less any applicable withholding taxes, in exchange for your shares of Hospira common stock. All shares converted into the right to receive the merger consideration will automatically be canceled at the effective time of the merger.

For Hospira registered shareholders, Pfizer has appointed Computershare Trust Company, N.A. (“Computershare”) as paying agent for payment of the merger consideration. Information concerning the exchange of Hospira shares for the per share merger consideration has been mailed to Hospira registered shareholders, outlining the steps to be taken to obtain the merger consideration. Registered shareholders do not need to take any action regarding their shares until contacted by the paying agent. For additional information, please contact Computershare at 1-800-546-5141 (within the U.S., its territories and Canada) or +1-781-575-2765 (outside the U.S., its territories and Canada).

If you own your shares through a bank, brokerage firm or other nominee (in “street name”), please contact your bank, broker or nominee for further information about receiving the merger consideration.

Effective October 27, 2011 Pfizer Inc. completed its acquisition of Icagen, Inc. Pursuant to the terms of the merger, former Icagen shareholders will receive $6.00, in cash (without interest and less any applicable withholding and transfer taxes) for each share of Icagen common stock they owned as of the effective time of the merger.

Pfizer has appointed American Stock Transfer & Trust Company, LLC as paying agent for payment of the merger consideration. Additional information will be mailed to Icagen registered shareholders outlining the steps to be taken to obtain the merger consideration. Shareholders do not need to take any action regarding their shares until contacted by the paying agent. For additional information, please contact American Stock & Trust Company at 1-877-248-6417 or +1-718-921-8317

Effective February 28, 2011 Pfizer Inc. completed its acquisition of King Pharmaceuticals, Inc. Pursuant to the terms of the merger, former King shareholders will receive $14.25, net in cash (without interest and less any required holding taxes) for each share of King common stock they owned as of the effective date.

Pfizer has appointed American Stock Transfer & Trust Company, LLC as paying agent for payment of the merger consideration. For information, please contact American Stock & Trust Company at 1-877-248-6417 or +1-718-921-8317.

Notice of Fundamental Change for Holders of King's 1¼% Convertible Senior Notes due 2026 (PDF).

On October 16, 2009 Pfizer completed its acquisition of Wyeth. For every one (1) share of Wyeth common stock that you held immediately prior to the closing of the merger, you are entitled to receive a combination of $33.00 in cash, without interest, and 0.985 of a share of Pfizer Inc. (“Pfizer”) common stock (referred to as the “merger consideration”). Pfizer will not issue any fractional shares of Pfizer common stock in the merger. Wyeth stockholders who would otherwise be entitled to a fractional share of Pfizer common stock will instead receive an amount in cash for such fractional share.

Frequently Asked Questions

On June 24, 2013, Pfizer Inc. (“Pfizer”) accepted 405,117,195 shares of Pfizer common stock validly tendered in exchange for 400,985,000 shares of common stock of Zoetis Inc. (“Zoetis”), representing all of the Zoetis stock then owned by Pfizer (the “Exchange”). Pursuant to the Exchange, tendering Pfizer shareholders received 0.9898 of a share of Zoetis common stock in exchange for each share of Pfizer common stock validly tendered and accepted by Pfizer. Pfizer shareholders also received cash in lieu of the fractional shares of Zoetis common stock that such Pfizer shareholders would otherwise have received in the Exchange.

Important Tax Information